Article

Keratocyte proliferation less after 213-nm solid-state laser

Corneal cell responses after PRK performed with a 213-nm solid-state and a 193-nm excimer laser were compared in a rabbit model. The results showed that both lasers have similar cell death-inducing properties, but less keratocyte proliferation followed treatment with the 213-nm laser.

Key Points

New Orleans-Results of an animal study show that less keratocyte proliferation occurs after surface ablation performed with a 213-nm solid-state laser compared with a 193-nm excimer laser, reported Paul P. van Saarloos, MSc, PhD, at the annual meeting of the American Academy of Ophthalmology.

"Since proliferating keratocytes may transform into activated fibroblasts that give rise to haze, the findings in this study suggest the 213-nm laser is potentially superior to the 193-nm excimer laser as a tool for refractive surgery," said Dr. van Saarloos, chief executive officer, CustomVis, Perth, Australia.

"In fact, in animal studies with longer follow-up after PRK treatment with the two lasers, both groups healed well, but there was evidence of less haze following treatment with the 213-nm laser. In addition, in clinical experience using the 213-nm laser for surface treatments, we are definitely seeing better stability and some suggestion of less haze compared with 193-nm excimer laser procedures."

Energy source

"The 213-nm wavelength is absorbed about 20-fold less in balanced salt solution and about 10,000 times less in normal saline. However, 193-nm and 213-nm have a similar absorption spectrum in corneal tissue," Dr. van Saarloos said. "Together, this information suggests 213-nm energy is absorbed more by corneal collagen than 193 nm. This suggests the ablation process is more efficient with 213-nm energy, with less energy wasted heating fluids and less heat generated that can damage surrounding tissue."

The animal study Dr. van Saarloos reported was performed independently by researchers at the University of Western Australia using New Zealand white rabbits. Groups of animals underwent identical PRK treatments for –5.00 D of sphere with a 6.5-mm optical zone and 7-mm translational zone using one of the two lasers. Animals within each group then were selected to be killed on post-treatment days 1 and 3 for evaluation of the corneas using immunohistochemical staining techniques to identify apoptotic cells and proliferating keratocytes. Frozen sections were cut, and six photographs of each section were taken, including two inside the laser-created crater, two at the edge of the crater within the transition zones, and two from non-lasered portions of the cornea.

At 1 day after both treatments, the epithelium had not yet recovered. Eyes treated with the 193-nm excimer laser had higher levels of both apoptotic cells and keratocytes beneath the ablative zone compared with eyes in the 213-nm solid-state laser group, although the differences between groups were not statistically significant.

At 3 days after surgery, the number of apoptotic cells had decreased to nearly zero in both groups, but the number of keratocytes was significantly higher in eyes treated with the 193-nm laser.

Dr. van Saarloos also noted that previous studies suggest the rabbit eyes provide a good representative model for outcomes in human eyes, with the major difference being that the healing responses to laser treatment occur much faster in the animals.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.